NCT03370302View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

August 28, 2019

Study Completion Date

August 28, 2019

Conditions
Advanced Nonhematological Neoplasms
Interventions
DRUG

TAK-228

TAK-228 Capsules.

Trial Locations (4)

100

National Taiwan-University Hospital, Taipei

277-8577

National Cancer Center Hospital East, Kashiwa-shi

104-0045

National Cancer Center Hospital, Chūōku

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY